Dry powder formulations for inhalation require a smaller aerodynamic diameter for usage at high altitude.
暂无分享,去创建一个
Shuo Liu | Liqun Jiang | Sujia Si | Ya Xu | Huiyang Li | Bingmei Yao | Wenjin Dai | Nan Sun | Jian Wang
[1] Peng Han,et al. Cepharanthine Dry Powder Inhaler for the Treatment of Acute Lung Injury , 2023, Molecules.
[2] M. S. Islam,et al. Nanoparticle transport and deposition in a heterogeneous human lung airway tree: An efficient one path model for CFD simulations. , 2022, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[3] E. Selg,et al. Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles. , 2022, International journal of pharmaceutics.
[4] A. Aliverti,et al. Functional analysis of the airways after pulmonary lobectomy through computational fluid dynamics , 2022, Scientific Reports.
[5] F. Mohamadi,et al. A Review on Applications of CFD Modeling in COVID-19 Pandemic , 2022, Archives of Computational Methods in Engineering.
[6] S. Ibrić,et al. Comparative Assessment of In Vitro and In Silico Methods for Aerodynamic Characterization of Powders for Inhalation , 2021, Pharmaceutics.
[7] A. Aliverti,et al. Computational Fluid Dynamics (CFD) Analysis of Subject-specific Bronchial Tree Models in Lung Cancer Patients , 2021, 2021 43rd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC).
[8] E. Molina-Grima,et al. CFD-based prediction of initial microalgal adhesion to solid surfaces using force balances , 2021, Biofouling.
[9] H. Chan,et al. Dry Powder Pharmaceutical Biologics for Inhalation Therapy. , 2021, Advanced drug delivery reviews.
[10] H. Ghofrani,et al. Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders , 2021, International journal of environmental research and public health.
[11] Raghvendra Gupta,et al. Flow and Particle Modelling of Dry Powder Inhalers: Methodologies, Recent Development and Emerging Applications , 2021, Pharmaceutics.
[12] D. Tripathi,et al. Bioengineered bioreactors: a review on enhancing biomethane and biohydrogen production by CFD modeling , 2021, Bioengineered.
[13] Runyu Yang,et al. Role of CFD based in silico modelling in establishing an in vitro-in vivo correlation of aerosol deposition in the respiratory tract. , 2020, Advanced drug delivery reviews.
[14] C. Darquenne. Deposition Mechanisms. , 2020, Journal of Aerosol Medicine.
[15] M. Nikinmaa. Finally, a promising model for high‐altitude pulmonary edema (HAPE)—A Mountaineers’ Malady , 2020, Acta physiologica.
[16] Y. Kagawa,et al. Small-Scale Spherical Granulation Using a Planetary Centrifugal Mixer. , 2020, Chemical and pharmaceutical bulletin.
[17] Basanth Babu Eedara,et al. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis. , 2019, International journal of pharmaceutics.
[18] C. Burger,et al. Twelve-Year Survival in a Patient With Systemic Sclerosis–Associated Pulmonary Arterial Hypertension on Nifedipine Monotherapy , 2019, Mayo Clinic proceedings. Innovations, quality & outcomes.
[19] M. Sommerfeld,et al. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[20] M. Hindle,et al. Use of computational fluid dynamics deposition modeling in respiratory drug delivery , 2018, Expert opinion on drug delivery.
[21] Xiaoting Yang,et al. Sinomenine protects against E.coli-induced acute lung injury in mice through Nrf2-NF-κB pathway. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[22] P. Young,et al. Dosing challenges in respiratory therapies , 2018, International journal of pharmaceutics.
[23] S. Ibrić,et al. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically‐based pharmacokinetic (PBPK) modelling , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[24] Michael Y. T. Chow,et al. Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer. , 2017, International journal of pharmaceutics.
[25] C. Grandmont,et al. Aerosol transport throughout inspiration and expiration in the pulmonary airways , 2017, International journal for numerical methods in biomedical engineering.
[26] I. Arévalo-Rodriguez,et al. Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs. , 2017, The Cochrane database of systematic reviews.
[27] Kazunori Kadota,et al. Assistance for Predicting Deposition of Tranilast Dry Powder in Pulmonary Airways by Computational Fluid Dynamics , 2017, Journal of Pharmaceutical Innovation.
[28] Boyi Niu,et al. Influence of physical properties of carrier on the performance of dry powder inhalers , 2016, Acta pharmaceutica Sinica. B.
[29] M. Delichatsios,et al. Blow-out limits of nonpremixed turbulent jet flames in a cross flow at atmospheric and sub-atmospheric pressures , 2015 .
[30] S. Lee,et al. Validating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo Data , 2015, Pharmaceutical Research.
[31] A. Nitsch-Osuch,et al. High altitude pulmonary edema in mountain climbers , 2015, Respiratory Physiology & Neurobiology.
[32] Mao-tsun Lin,et al. High-altitude pulmonary edema can be prevented by heat shock protein 70–mediated hyperbaric oxygen preconditioning , 2014, The journal of trauma and acute care surgery.
[33] L. Chua,et al. Perspective on CFD studies of coronary artery disease lesions and hemodynamics: A review , 2014, International journal for numerical methods in biomedical engineering.
[34] E. Swenson,et al. Clinical practice: Acute high-altitude illnesses. , 2013, The New England journal of medicine.
[35] Waseem Kaialy,et al. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate. , 2012, International journal of pharmaceutics.
[36] R. Löbenberg,et al. Pulmonary delivery of inhalable nanoparticles: dry powder inhalers. , 2011, Therapeutic delivery.
[37] Raymond Lau,et al. Effect of particle formulation on dry powder inhalation efficiency. , 2010, Current pharmaceutical design.
[38] P. Hackett,et al. Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness , 2010, Wilderness & environmental medicine.
[39] Beom-Jin Lee,et al. Circadian variations in the pharmacokinetics, tissue distribution and urinary excretion of nifedipine after a single oral administration to rats , 2005, Biopharmaceutics & drug disposition.
[40] J. Borer,et al. Nifedipine in pulmonary arterial hypertension. Importance of Raynaud's phenomenon. , 1987, Chest.
[41] J. Sommer,et al. Pharmacokinetics and metabolism of nifedipine. , 1983, Hypertension.
[42] S. Watano,et al. Effect of Particle-Wall Interaction and Particle Shape on Particle Deposition Behavior in Human Respiratory System. , 2019, Chemical & pharmaceutical bulletin.
[43] S. Wagner,et al. Computational Fluid Dynamics (CFD) , 2000 .